Normal immunoglobulin



General description

Immunoglobulin therapy, also known as normal human immunoglobulin (NHIG), is the use of a mixture of antibodies (immunoglobulins) to treat primary immunodeficiency and Kawasaki disease.

ATC codes	J06BA02
Medicine type	Biological agent
EML status history	First added in 1977 (TRS 615) for Primary immunodeficiencies Changed in 1977 (TRS 615) for Mucocutaneous lymph node syndrome Removed in 2003 (TRS 920) for Primary immunodeficiencies Changed in 2003 (TRS 920) for Mucocutaneous lymph node syndrome Added in 2007 (TRS 946) for Primary immunodeficiencies Changed in 2007 (TRS 946) for Mucocutaneous lymph node syndrome Changed in 2023 (TRS 1049) for Langerhans cell histiocytosis Changed in 2025 (TRS 1064) for Acute inflammatory demyelinating polyneuropathy
Wikipedia	Normal immunoglobulin
DrugBank	Normal immunoglobulin (Immune Globulin Human)

Recommendations

Section Human immunoglobulins

- Parenteral > General injections > IV: 5% protein solution; 10% protein solution
- Parenteral > General injections > IM: 16% protein solution
- Parenteral > General injections > SC: 15% protein solution; 16% protein solution

Indications

Primary immunodeficiencies

Mucocutaneous lymph node syndrome

Langerhans cell histiocytosis

Section Medicines for Guillain-Barré syndrome

- Parenteral > General injections > IV: 5% protein solution; 10% protein solution

Indications

Acute inflammatory demyelinating polyneuropathy